Search Results

Containing any of the words

Only of the type

A Phase 3b Study to Evaluate Efficacy and Safety of a Single Dose of Autologous CRISPR Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects with Transfusion-Dependent β-Thalassemia or Severe Sickle Cell Disease Drug Clinical Trial

Low INR to Minimize bleeding with mechanical valves Trial (LIMIT) Drug Clinical Trial

(WU2406) NCMDR Weakly Update Medical Report

Inclisiran Risk Minimization Activity - New

Voriconazole Risk Minimization Activity - New

DABIGATRAN Risk Minimization Activity - New

Micafungin Risk Minimization Activity - New

Dr. Salah bin Muhammad Al-Eid head of board

Dr. Fahd bin Ibrahim Al-Janubi head of board

Mr. Abdulmohsen bin Fahd Al-Mazini head of board